Abstract
Objectives To determine if specific ethnic groups are at higher risk of mortality from COVID19 infection.
Design Retrospective cohort study
Setting University Hospitals Birmingham NHS Foundation Trust (UHB) in Birmingham, UK
Participants Patients with confirmed SARS-CoV-2 infection requiring admission to UHB between 10th March 2020 and 17th April 2020
Exposure Ethnicity
Main outcome measures Standardised Admission Ratio (SAR) and Standardised Mortality Ratio (SMR) for each ethnicity was calculated using observed sex-specific age distributions of COVID-19 admissions/deaths and 2011 census data for Birmingham/Solihull. Hazard Ratio (aHR) for mortality was estimated for each ethnic group with white population as reference group, using Cox proportional hazards model adjusting for age, sex, social deprivation and co-morbidities, and propensity score matching.
Results 2217 patients admitted to UHB with a proven diagnosis of COVID-19 were included. 58.2% were male, 69.5% White and the majority (80.2%) had co-morbidities. 18.5% were of South Asian ethnicity, and these patients were more likely to be younger (median age 61 years vs.77 years), have no co-morbidities (27.8% vs. 16.6%) but a higher prevalence of diabetes mellitus (48.0% vs 28.2%) than White patients. SAR and SMR suggested more admissions and deaths in South Asian patients than would be predicted. South Asian patients were also more likely to present with severe disease despite no delay in presentation since symptom onset. South Asian ethnicity was associated with an increased risk of death; both by Cox regression (Hazard Ratio 1.66 (95%CI 1.32 – 2.10)) after adjusting for age, sex, deprivation and comorbidities and by propensity score matching, (Hazard ratio 1.68 (1.33–2.13), using the same factors but categorising ethnicity into South Asian or not.
Conclusions Current evidence suggests those of South Asian ethnicity may be at risk of worse COVID-19 outcomes, further studies need to establish the underlying mechanistic pathways.
Evidence before Published studies of the evolving COVID-19 pandemic have suggested risk factors for the most severe manifestations of the disease, including increasing age, male sex and co-morbidities, especially hypertension, cardiovascular disease and diabetes. There have been observations suggesting poorer outcomes for patients of some ethnicities, and understanding this has become a global priority.
Added value Although still an emerging picture, initial data from our multi-ethnic cohort suggests there are more admissions from South Asian patients than would be expected based on our population, these patients are admitted with a worse severity of COVID19 related respiratory compromise without a significant delay in presentation and experience a higher level of mortality even when differences in age, sex, deprivation and key comorbidities were taken into account. This was consistently shown using different statistical methods.
Implications South Asian ethnicity may form another ‘at risk’ population from COVID-19. However, further studies are needed to better understand the underlying reasons, in particular any modifiable factors to improve outcomes as well as to refine our understanding and communication around non-modifiable risk factors.
Competing Interest Statement
S Gallier, C Mainey, P Nightingale, D McNulty, H Crothers, F Evison, D Pagano, report no conflicts of interest. S Ball and P Diggle reports funding support from HDRUK, K Reeves reports funding support from the NIHR, E Sapey reports funding support from HDRUK, MRC, Wellcome Trust, NIHR and British Lung Foundation. K Nirantharakumar reports funding from MRC, Wellcome Trust, NIHR, Vifor and AstraZeneca. AK Denniston reports funding from HDRUK, Wellcome Trust and Fight for Sight.
Funding Statement
This work was funded by the HDR-UK Health data and Research Hub in Acute Care: PIONEER
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
To facilitate knowledge in this area, the anonymised participant data and a data dictionary defining each field will be available to others through application to DECOVID via the corresponding author. The data will be available upon request and following approval of a process to ensure ethical data governance and through a data access agreement. Please contact the corresponding author for details.
